Clinical Trials Browser

Phase 3 × pembrolizumab × Genitourinary × Clear all

NCT07218380 2026-03-19

FORAGER-2

Phase 3 Recruiting

Urinary Bladder Neoplasms, Carcinoma, Transitional Cell, Neoplasm Metastasis

NCT06524544 2026-03-18

A Study Comparing the Combination of Pembrolizumab and Sacituzumab Govitecan Versus Standard of Care in the Treatment of Advanced Urothelial Cancer

Phase 3 Recruiting

Carcinoma, Transitional Cell

NCT03142334 2026-03-10

KEYNOTE-564

Phase 3 Completed

994 enrolled 10 charts 1 FDA

Parkinson Disease 4, Autosomal Dominant Lewy Body, Carcinoma, Renal Cell

NCT06661720 2026-03-04

STRIKE

Phase 3 Recruiting

Carcinoma, Renal Cell

NCT02811861 2026-02-23

CLEAR

Phase 3 Active not recruiting

1,069 enrolled 12 charts 1 FDA

Carcinoma, Renal Cell

NCT03898180 2026-02-05

LEAP-011

Phase 3 Completed

505 enrolled 19 charts

Parkinson Disease 4, Autosomal Dominant Lewy Body, Carcinoma, Transitional Cell

NCT04700124 2026-02-05

KEYNOTE-B15

Phase 3 Completed

Parkinson Disease 4, Autosomal Dominant Lewy Body, Urinary Bladder Neoplasms

NCT02853331 2026-02-02

KEYNOTE-426

Phase 3 Completed

861 enrolled 24 charts 1 FDA

Carcinoma, Renal Cell

NCT03390504 2026-02-02

THOR

Phase 3 Active not recruiting

629 enrolled 32 charts 1 FDA

Urothelial Cancer

NCT07346053 2026-01-16

Chrono-EVP

Phase 3 Not yet recruiting

Advanced Bladder Cancer

NCT04157985 2025-12-11

Evaluating Length of Treatment With PD-1/PD-L1 Inhibitor in Advanced Solid Tumors

Phase 3 Completed

DermatologicGastrointestinalGenitourinaryGynecologicHead & Neck

Squamous Cell Carcinoma of Head and Neck, Anus Neoplasms, Urinary Bladder Neoplasms, Uterine Cervical Neoplasms, Carcinoma, Hepatocellular, Kidney Neoplasms, Melanoma, Stomach Neoplasms, Colorectal Neoplasms, Carcinoma, Merkel Cell, Cholangiocarcinoma

NCT05899049 2025-11-10

A Study of Pembrolizumab (MK-3475) in Combination With Belzutifan (MK-6482) and Lenvatinib (MK-7902), or Pembrolizumab/Quavonlimab (MK-1308A) in Combination With Lenvatinib, vs Pembrolizumab and Lenvatinib, for Treatment of Advanced Clear Cell Renal Cell Carcinoma (MK-6482-012)-China Extension Study

Phase 3 Active not recruiting

Parkinson Disease 4, Autosomal Dominant Lewy Body, Carcinoma, Renal Cell

NCT03924856 2025-08-28

KEYNOTE-866

Phase 3 Active not recruiting

Parkinson Disease 4, Autosomal Dominant Lewy Body, Urinary Bladder Neoplasms

NCT03374488 2025-08-22

Pembrolizumab + Epacadostat vs Pembrolizumab + Placebo in Recurrent or Progressive Metastatic Urothelial Carcinoma

Phase 3 Completed

84 enrolled 13 charts

Parkinson Disease 4, Autosomal Dominant Lewy Body, Carcinoma, Transitional Cell

NCT05239728 2025-08-14

MK-6482-022

Phase 3 Active not recruiting

Parkinson Disease 4, Autosomal Dominant Lewy Body, Carcinoma, Renal Cell

NCT03260894 2025-07-29

Pembrolizumab (MK-3475) Plus Epacadostat vs Standard of Care in mRCC (KEYNOTE-679/ECHO-302)

Phase 3 Completed

129 enrolled 13 charts

Parkinson Disease 4, Autosomal Dominant Lewy Body, Carcinoma, Renal Cell

NCT03834493 2025-07-18

KEYNOTE-641

Phase 3 Active not recruiting

1,244 enrolled 21 charts

Parkinson Disease 4, Autosomal Dominant Lewy Body, Prostatic Neoplasms

NCT03834506 2025-07-18

KEYNOTE-921

Phase 3 Completed

1,030 enrolled 24 charts

Parkinson Disease 4, Autosomal Dominant Lewy Body, Prostatic Neoplasms

NCT04223856 2025-06-13

EV-302

Phase 3 Active not recruiting

886 enrolled 12 charts 1 FDA

Urothelial Cancer

NCT03834519 2025-05-18

KEYLYNK-010

Phase 3 Completed

793 enrolled 23 charts

Parkinson Disease 4, Autosomal Dominant Lewy Body, Prostatic Neoplasms

NCT06364631 2025-01-16

CARE1

Phase 3 Recruiting

Carcinoma, Renal Cell, Kidney Neoplasms

NCT04637594 2025-01-15

IMAGINE

Phase 3 Active not recruiting

Carcinoma, Transitional Cell

NCT04241185 2024-11-25

MK-3475-992

Phase 3 Active not recruiting

Urinary Bladder Neoplasms

NCT04736706 2024-11-18

MK-6482-012

Phase 3 Active not recruiting

Parkinson Disease 4, Autosomal Dominant Lewy Body, Carcinoma, Renal Cell

NCT04907227 2024-07-12

KEYNOTE-921

Phase 3 Terminated

81 enrolled 19 charts

Parkinson Disease 4, Autosomal Dominant Lewy Body, Prostatic Neoplasms

NCT06146777 2023-11-29

Multi-classifier System for Stratifying Stage III Papillary Renal Cell Carcinoma of Receiving Adjuvant Therapy

Phase 3 Not yet recruiting

Carcinoma, Renal Cell

NCT02256436 2021-09-20

MK-3475-045

Phase 3 Completed

542 enrolled 31 charts

Parkinson Disease 4, Autosomal Dominant Lewy Body, Urinary Bladder Neoplasms